Telaprevir- and boceprevir-based triple therapy for hepatitis C in liver transplant recipients with advanced recurrent disease: A multicenter study

Transplantation

Volumn 99, Issue 8, 2015, Pages 1644-1651

  Verna, Elizabeth C ^a   Saxena, Varun ^b   Burton, James R ^c   O'Leary, Jacqueline G ^d   Dodge, Jennifer L ^b   Stravitz, Richard T ^e   Levitsky, Josh ^f   Trotter, James F ^d   Everson, Gregory T ^c   Brown, Robert S ^a   Terrault, Norah A ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BOCEPREVIR; CYCLOSPORIN; INTERFERON; INTERLEUKIN 28B; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PREDNISONE; STEROID; TACROLIMUS; TELAPREVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; ASCITES; BRAIN DISEASE; CAUSE OF DEATH; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT WITHDRAWAL; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CHOLESTASIS; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; HEPACIVIRUS; LIVER CIRRHOSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; BIOMARKERS; CHOLESTASIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OLIGOPEPTIDES; PROLINE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84942474802     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000629     Document Type: Article

References (54)

1. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010;10:1003-1019.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896.
3. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46:459-465.
4. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008;8:679-687.
5. Bizollon T PP, Mabrut JY, Chevallier M, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant. 2005;5:1909-1913.
6. Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patientswith recurrent hepatitis C infection. Am J Transplant. 2008;8:2426-2433.
7. Crespo G, Carrion JA, Coto-Llerena M, et al. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol. 2013;48: 762-769.
8. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat. 2008;15:699-709.
9. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peginterferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007;46:1009-1017.
10. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746-1756.
11. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl. 2008;14:53-58.
12. Berenguer M, Schuppan D. Progression of liver fibrosis in posttransplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028-1041.
13. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14: 1766-1777.
14. Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol. 2012;56:1310-1316.
15. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEGinterferon and ribavirin. Am J Transplant. 2006;6:2348-2355.
16. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32:852-858.
17. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol. 2006;45:127-143.
18. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl. 2009;15:738-746.
19. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274-287.
20. Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A. Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. World J Gastroenterol. 2013;19:3255-3262.
21. Ong JP, Younossi ZM, Gramlich T, et al. Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation. 2001;71: 1486-1487.
22. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl. 2003;9:348-353.
23. Satapathy SK, Sclair S, Fiel MI, Del Rio Martin J, Schiano T. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res. 2011;41: 328-339.
24. Duarte-Rojo A, Budhraja V, Veldt BJ, et al. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: A case-control study and literature review. Liver Transpl. 2013;19:1311-1317.
25. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360:1827-1838.
26. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferonwith or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360:1839-1850.
27. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
28. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 376: 705-716.
29. Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl JMed. 2011;364:1195-1206.
30. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-1303.
31. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl JMed. 2011;364:2417-2428.
32. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364: 1207-1217.
33. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatmentexperienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol. 2013;59:431-441.
34. Colombo M, Fernandez I, Abdurakhmanov D, et al. Safety and ontreatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut. 2014;63:1150-1158.
35. Ogawa E, Furusyo N, Nakamuta M, et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther. 2013;38:1076-1085.
36. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147:132-142.
37. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20-27.
38. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012;56:1622-1630.
39. O'Leary JG, McKenna GJ, Klintmalm GB, Davis GL. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl. 2013;19:463-465.
40. Burton JR, O'Leary JG, Verna EC, et al. A USmulticenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014;61:508-514.
41. Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19:78-88.
42. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1-S9.
43. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60:78-86.
44. Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013;19:690-700.
45. Kwo PY, Ghabril M, Lacerda MA, Joseph Tector A, Fridell JA, Vianna R. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. Clin Transplant. 2014;28:722-727.
46. Werner CR, Egetemeyr DP, Nadalin S, et al. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z Gastroenterol. 2014;52:27-34.
47. Faisal N, Renner EL, Bilodeau M, et al. Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: a Canadian multicenter experience. Hepatology. 2013;58:238A.
48. Faisal N, Yoshida EM, Bilodeau M, et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol. 2014;13:525-532.
49. Fernandez I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl. 2006;12:1805-1812.
50. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl. 2012;18:1053-1059.
51. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601-1605.
52. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation. J Hepatol. 2015;148:108-117.
53. Forns X, Prieto M, Charlton M, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. J Hepatol. 2015;61:1485-1494.
54. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16:1228-1235.